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Although MMP-28 is involved in numerous important physiologic and pathologic conditions, the mechanisms of action of this
secreted proteinase is not well understood. We now have demonstrated that furin serves as an intermolecular chaperone for MMP-
28 secretion by interacting with the propeptide domain of MMP-28. Employing COS-1 cells transfected with MMP-28 cDNA,
protein levels of MMP-28 were quite low in conditioned media as compared to cell lysates. Coexpression of MMP-28 with furin
cDNA resulted in markedly enhanced MMP-28 secretion. Contrary to expectation, cleavage of MMP-28 at the furin consensus
sequence did not occur and proteolytic inactive furin was equally eﬀective in enhancing MMP-28 secretion. Furin and MMP-
28 coimmunoprecipitated and were partially coimmunolocalized in the cytoplasm of transfected cells. Cotransfection with furin
cDNA also enhanced MMP-28 induced cell migration. In conclusion, our data provide a novel mechanism for MMP-28 function
in cells in which furin serves as an intermolecular chaperone.
1.Introduction
In the four decades following the discovery of an amphibian
collagenase [1], our understanding of matrix metallopro-
teinases (MMPs) has evolved from distinction between
MMP family members based on substrate preferences, to
nucleotide and amino acid sequencing, and most recently, to
structural-functional characteristics [2, 3]. MMPs are impli-
cated in extracellular matrix degradation, cell migration,
proliferation, apoptosis, and tissue remodeling in numerous
biologicandpathologicconditions[2–5].Thebasicstructure
of the zinc-binding region within the catalytic domain and
the cysteine switch sequence within the propeptide domain
i sp r e s e r v e di n2 3o f2 4h u m a nM M P s[ 5]. All six membrane
type MMPs (MT-MMPs) also contain a paired basic amino
acid sequence (Arg-X-Lys/Arg-Arg) located between the N-
terminal propeptide domain and catalytic domain. This
unique motif facilitates cleavage and activation of these
proteinases by proprotein convertases, such as furin [6]. The
furin activation sequence has also been identiﬁed in selected
secreted MMPs including MMP-11, MMP-21, MMP-23, and
the most recently identiﬁed, MMP-28 [7–9].
Furin, a ubiquitously expressed member of the pro-
protein/convertase family, primarily functions in cells
by processing inactive precursor proteins to their func-
tional/mature forms [10, 11]. Less often, furin processing of
propeptides (proADAMTS9 and proMMP-2) can diminish
function of the mature protein [12, 13]. Furin is localized
primarily in the trans-Golgi network (TGN), a late Golgi
structure that is responsible for sorting secretory pathway
proteins to their ﬁnal destinations. From the TGN, furin
follows a highly regulated traﬃcking itinerary through
several TGN/endosomal compartments and the cell surface
[14]. Furin cleaves proproteins on the C-terminal side of the2 Biochemistry Research International
consensus sequence -Arg-X-Lys/Arg-Arg in the TGN [15].
Arg residues at the P1 and P4 positions of the cleavage
site are essential, whereas the P2 basic amino acid is not
essential, but serves to enhance processing eﬃciency. Hence,
RXXR represents the minimal furin cleavage site. Furin is
upregulated in several cancers, including nonsmall cell lung
carcinomas, squamous cell carcinomas of the head and neck,
breast carcinomas, ovarian carcinomas, and glioblastomas
[16–22]. Elevated expression of furin results in increased
tumor cell migration, invasion, and metastasis. In addition
to conversion of proproteins to activated forms, furin has
also been found to promote protein traﬃcking, including
latentMT1-MMP[23];themechanismunderlyingenhanced
proprotein traﬃcking remains to be understood.
H u m a nM M P - 2 8[ 24] was initially designated as epilysin
based on presumed speciﬁc expression in keratinocytes.
Furin was subsequently cloned from human testis [24]a n d
lung cDNA libraries [25]. The protein contains all of the
typical MMP domains. MMP-28 is also expressed to a lesser
degree in other normal, intact tissues including the gas-
trointestinal tract, lung, kidney, heart, skeletal muscle, and
nervous system. Recombinant MMP-28 has been reported to
degradecasein[24],Nogo-A(amyelincomponent),NCAM-
1[ 26] and slowly cleaves a pan-MMP ﬂuorogenic substrate
[26]. With the exception of keratinocytes, basal expression
of MMP-28 has been reported to be quite low among other
cell lines [27]. Among 12 growth factors tested, only tumor
necrosis factor α has been reported to upregulate MMP-28
mRNA; MMP-28 expression appears not to be modulated
by extracellular matrices. MMP-28 expression is tightly
regulated and has been implicated in tissue homeostasis
[24, 28], in cell proliferation during wound repair [27], and
in neuronal development and demyelination [26]. Little is
known about in vivo substrates and activators of MMP-
28 [27]. Xenopus MMP-28 has been demonstrated to be
activated by furin in vivo [26]. Illman et al. [29]r e p o r t e d
that overexpression of MMP-28 in lung adenocarcinoma
cells induced an epithelial-to-mesenchymal transition and
cell invasion requiring the catalytic activity of MMP-28
and cell surface localization mediated by the hemopexin
domain of MMP-28. This epithelial-to-mesenchymal transi-
tion involved activation of the TGF-β mechanism followed
by upregulation of MT1-MMP and MMP-9. Cell migration
of these EMT cells was independent of MMP activity.
Although propeptide domains of MMPs are best known
for maintaining the protease in an inactive state, we pre-
viously demonstrated that the propeptide domain of MT1-
MMP functions as a intramolecular chaperone required
for traﬃcking and function of the protease on the cell
surface [30]. Alanine substitution mutations revealed that
ac o n s e r v e dt e t r a p e p t i d e( T y r 42-Gly43-Tyr44-Leu45) within
the propeptide of MT1-MMP was crucial for the chaperone
functionoftheprodomaininvolvingtraﬃckingoffunctional
MT1-MMP to the plasma membrane [31]. Of interest, the
YGYL tetrapeptide is fully conserved in human as well as rat,
mouse, and Xenopus laevis MMP-28 [9, 26]. The function of
the YGYL in MMP-28 is still unknown. Based on the unique
function of this peptide in MT1-MMP [31], we have herein
examined the role of YGYL in the propeptide domain of
MMP-28. An important function for the YL motif on cell
secretion of MMP-28 has been demonstrated. The formation
of an intracellular protein complex between latent furin and
the prodomain of MMP-28 appears to play a critical role in
secretion and function of this protease.
2.MaterialsandMethods
2.1. Reagents. Oligo primers were purchased from Operon
(Al, Huntsville). pcDNA3.1 and expression vectors were
purchased from Invitrogen (Carlsbad, CA). Anti-Myc mon-
oclonal antibody was purchased from Roche (Indianapolis,
IN). Antifurin polyclonal antibodies were purchased from
Santa Cruz (Santa Cruz, CA). Anti-MT1-MMP hinge anti-
body was purchased from Triple Point Biologics (Forest
Grove, OR). Anti-tubulin antibody was purchased from Cell
Signaling Technology (Davers, MA). Alexa 568-conjugated
goat anti-mouse IgG was purchased from Invitrogen (Carls-
bad, CA). Endoglycosidase H and peptide:N-glycosidase
F were purchased form Roche (Indianapolis, IN) and
NEB (Ipswich, MA), respectively. Wild-type, soluble, and
dominant negative furin (furin
S-A) cDNAs were described
previously [32]. MT1-MMP, its chimeras [33]a n dM M P - 2 8
cDNA [24]w e r ep r e v i o u s l yr e p o r t e d .
2.2. Cell Culture and Transfection. COS-1 cells were pur-
chased from ATCC (Manassas, VA) and were maintained in
Dulbecco’s modiﬁed Eagle’s medium (Invitrogen). Plasmids
were transfected into COS-1 cells using Transfectin reagent
(Bio-Rad, CA). Transfected cells were incubated for 48h at
37◦C in DMEM containing 10% fetal calf serum (FCS).
2.3. Construction of Plasmids. MMP-28 with a carboxy-
terminal Myc tag (MMP-28/Myc) was generated using the
pcDNA3.1 expression vector (Invitrogen). The MMP-28
cDNA containing the open reading frame of MMP-28 was
ampliﬁed by a PCR approach using the primers sets: forward
primer, number 1086: 5 -3 : AAGAATTCCGGCGAGATG-
GTCGCGCGCGTC and reverse primer, number 1117: 5 -
3  AAAAGCTTGAACAGGGCGCTCCCCGAGTTGGC. The
resultant PCR fragment was then cloned into the pcDNA3.1
vector at EcoR I and Hind III sites to generate MMP-28/Myc
chimeric cDNA.
To construct a constitutively inactive MMP-28/Myc
(MMP-28E241A/Myc), the glutamic acid (E241)o fM M P - 2 8
was converted to alanine by a PCR-based mutagenesis
approach using wild-type MMP-28/Myc as a template
with mutagenesis primers (forward primer, no. 1166,
5 -3 : TGGTGCTGGCGCACGCGATCGGTCACACGC and
reverse primer, no. 1167, 5 -3 : GCGTGTGACCGA-
TCGCGTGCGCCAGCACC) (underline letters represent
mutation site) (Quick Change Site-Directed Mutagenesis
kit, Stratagene) to generate MMP-28E241A. Using a
similar approach, MMP28R119KAA,M M P 2 8 Y43G44-AA,
and MMP28Y45L46-AA were generated with primer sets as
follow: MMP28R119KAA (forward, 5 -3 : ACCAAACTGAGG-
CGTAAGGCAGCCTTTGCAAAGCAAGGTAA, and reverseBiochemistry Research International 3
primer, 5 -3 : TTACCTTGCTTTGCAAAGGCTGCCTT-
ACGCCTCATTTTGGT);MMP28Y43G44-AA (forwardprimer,
5 -3 : GCGGAGGCATTCCTAGAGAAGGCCGCATAC-
CTCAATGAACAGGTCCCC, and reverse primer, 5 -3 :
GGGGACCTGTTCATTGAGGTATGCGGCCTTCTCTAG-
GAATGCCTCCGC); and MMP28Y45L46-AA (forward primer,
5 -3 : GCATTCCTAGAGAAGTACGGAGCCGCCAAT-
GAACAGGTCCCCAAAGCT; and reverse primer, 5 -3 :
AGCTTTGGGGACCTGTTCATTGGCGGCTCCGTACTT-
CTCTAGGAATGC). All constructs were veriﬁed by DNA
sequencing.
2.4. Immunoﬂuorescent Staining and Laser Scanning
Confocal Microscopy. C u l t u r e dc e l l sw e r eﬁ x e dw i t h4 %
Paraformaldehyde (PFA)/PBS followed by blocking with
3% BSA/PBS. MMP28-Myc and furin were detected by an
antibody against the Myc tag (MMP-28) and furin followed
by secondary antibodies conjugated with Alexa 568 and
FITC (Invitrogen). The immunostained cells were examined
using a Zeiss LSM 510 META NLO Two-Photon Laser
Scanning Confocal Microscope System.
2.5. Co-Immunoprecipitation. COS-1 cells cotransfected
with furin along with MMP-28/Myc or MT1-MMP/Myc
cDNAs were lysed with RIPA lysis buﬀer. An aliquot of the
original sample was also saved to assess protein expression
in the transfected cells by a Western blotting. The cell lysates
wereimmunoprecipitatedwithantifurinantibodiesfollowed
by capturing antigen-antibody complex with protein A
agarose beads (Invitrogen). Myc tagged MMP-28 and MT1-
MMPcomplexeswerefractionatedbySDS-PAGE(10%poly-
acrylamide gel) and Western blotting was performed using
anti-Myc antibodies. In reciprocal coimmunoprecipitation
experiments,celllysateswereimmunoprecipitatedwithanti-
Myc antibodies followed by Western blotting with antifurin
antibodies.
2.6. Digestion with EndoHand PNGase F. The cell lysate
of COS-1 cells transfected with MMP-28 and furin was
boiled for 10min in denaturing buﬀer containing 1% 2-
mercaptoethanol and 0.5% SDS to expose fully all glycosy-
lation sites, and then deglycosylation was done by treatment
with Endo H or PNGase F at 37◦Cf o r3h .T h eb u ﬀers used
in these enzyme reactions were 50 mM sodium citrate (pH
5.5) for Endo H and 50mM sodium phosphate (pH 7.5)
containing1%NonidetP-40forPNGaseF.Thesampleswere
then separated by SDS-PAGE followed by Western blotting
using anti-Myc antibody.
2.7.TranswellMigrationAssay. Polycarbonatemembranesof
13mm diameter with 8μmp o r es i z e( N e u r oP r o b e ,M D )
were inserted into the Blind-Well Chemotactic chambers
(Neuro Probe, MD). Prior to seeding into the transwell
inserts, COS-1 cells were released from plates with trypsin-
EDTA and 2 × 104 cells/well placed in the top chamber
of transwell migration chambers in triplicates. The lower
chamber was ﬁlled with DMEM containing 10% FCS
(200μL). After 6 hours, COS-1 cells that had not migrated
to the lower chamber were removed from the upper surface
of the transwell membrane with a cotton swab. Migrating
cells on the lower membrane surface were ﬁxed, stained with
0.1% crystal violet, and examined under a microscope. The
numberofcellsin10areasoftheﬁlterswascountedtoobtain
thenumberofmigratingcells.Eachexperimentwasrepeated
three times.
2.8. Statistical Analysis. Data are presented as mean ± SEM.
Employing GraphPad Prism 5, statistical signiﬁcance was
tested by using Student’s t-test (with ∗∗P<. 001 and ∗∗∗P<
.0005).
2.9. Procedures for Preparation of Cell Lysate and Western
Blotting. Basic protocols for these techniques have been
described in our recent paper [34].
3. Results
We previously demonstrated that the propeptide domain of
MT1-MMP acts as an intramolecular chaperone required
for traﬃcking and function of the proteinase on the plasma
membrane [30, 35, 36]. We further demonstrated that a
conserved 42YGYL45 sequence, which is present within the
propeptide of all six members of the MT-MMP subfamily,
appears critical for the intramolecular chaperone function
[31]. By analyzing the amino acid sequence of secretory
MMPs, the propeptide domains of MMP-19 and -28 were
noted to contains the same YGYL sequence and a RXXR
furin consensus motif as displayed in MT-MMPs (Figure 1).
These observations have led us to ponder whether the YGYL
sequence confers an analogous function in the secretion of
MMP-28.
3.1. Expression of MMP-28 in COS-1 Cells: Furin Facilitates
Secretion of MMP-28. To determine the requirement of the
YGYL motif within the propeptide domain in protein traf-
ﬁcking and secretion, MMP-28/Myc cDNA was transiently
transfected into COS-1 cells followed by Western blotting
using an anti-Myc antibody. Unexpectedly, (secreted) MMP-
28/Myc was barely detected in the cell conditioned medium
(Figure 2(a));mostoftherecombinantproteinwasidentiﬁed
in the cell lysate. Two MMP-28 bands with approximate
molecular mass of 56kDa and 52kDa were seen in the
cell lysate (Figure 2(a)). Other experiments were performed
to decipher the limited secretion of MMP-28. Diminished
secretion of MMP-28 was not due to malfunction of the
N-terminal signal peptide of MMP-28, since replacement of
the signal peptide cDNA of MMP-28 by that of MT1-MMP
did not enhance the secretion of MMP-28 chimera (data not
shown).
Since MMP-28 carries a RKKR furin consensus sequence
between the propeptide and catalytic domains (Figure 1), we
anticipated that furin in the Trans Golgi Network (TGN)
would cleave and activate MMP-28 prior to secretion,
resulting in two distinct molecules (see explanation below).
To test this possibility, COS-1 cells were cotransfected with
MMP-28/Myc along with furin or GFP (as control) cDNA.4 Biochemistry Research International
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Figure 1: Alignment of the propeptide domain of YGYL containing MMPs. The intramolecular chaperone sequence of YGYL, cysteine
switch sequence of PRCGVPD, and all conserved amino acids within the propeptide domains of MMPs are highlighted in black, and furin
consensus sequence of RXXR motif is highlight in gray. Blue line represents a signal peptide and red line represents propeptide domain.
After 18 hours, the conditioned media and cell lysates
were collected and immunoblotting was performed using
an anti-Myc antibody. Unexpectedly, coexpression of MMP-
28 with furin resulted in increased secretion of MMP-28
into conditioned media (Figure 2(a)). In contrast, the total
amount of MMP-28 in the cell lysate did not appear to be
aﬀectedbycoexpressionoffurin(Figure 2(a)).Relativelevels
of MMP-28 mRNA were not aﬀected by cotransfection with
furin cDNA, which minimizes a role for furin in regulation
of transcription (Figure 2(b)).
Although the molecular weight diﬀerence between the
doublet bands (56 and 52kDa) of MMP-28 in the cell lysate
was less than the ∼10kDa diﬀerence anticipated between
latent and activated MMPs, additional studies were needed
to determine if furin cleavage (activation) of proMMP-
28 was required for enhanced secretion. To this end, we
employed loss-of-function mutations of furin which were
previously reported [12]. Transfection of COS-1 cells with
inactive furin (Furin
S-A) cDNA or soluble furin (Sol.Furin)
cDNA [12]r e s u l t e di ne n h a n c e dM M P - 2 8s e c r e t i o n ;n o
eﬀect on the apparent molecular weight of MMP-28 was
noted between wild-type furin or mutant furin-transfected
cells (Figure 2(c)). Furthermore, transfection of COS-1 cells
with wild-type furin cDNA as well as MMP-28 cDNA
containing an alanine disrupted furin consensus sequence
(R119KAA instead of R119KKR) did not alter the secretion
of the MMP-28 doublet protein bands (Figure 2(d)). Using
another approach to determine if activation of proMMP-
28 is required prior to secretion, a glutamic acid to alanine
substitution mutation (E241-A) in the catalytic domain
was employed as a technique to generate a nonproteolytic
MMP [37]. Incubation of COS-1 cells transfected with
MMP-28 E241-A cDNA or incubation of wild-type MMP-
28 transfected COS-1 cells with a broad spectrum MMP
inhibitor (BB94, data not shown) did not abrogate furin-
induced secretion of MMP-28 (Figure 2(d)). Furthermore,
the conditioned media from COS-1 cells transfected with
MMP-28 or MMP-28 along with furin cDNAs did not show
signiﬁcant proteolytic activity using a ﬂuorogenic substrate
assay [38] (data not shown). These results suggest that furin
promotes the secretion of MMP-28 in COS-1 cells without
processing/cleavage of the latent form of the proteinase.
In view of the lack of evidence for proteolytic cleavage
to explain the doublet bands of MMP-28, we proceeded
to explore the report that MMP-28 is N-glycosylated
during secretory traﬃcking [39]. To test if MMP-28
expressed in COS-1 cells is glycosylated, the conditioned
medium from COS-1 cells cotransfected with MMP-28
and furin cDNAs was treated with endoglycosidase H and
peptide:N-glycosidase F (PNGase F). Endoglycosidase H
cleaves asparagine-linked oligomannose and hybrid, but not
complex, oligosaccharides from glycoproteins, generating
a truncated sugar molecule with one N-acetylglucosamine
residue remaining on the asparagine. In contrast, PNGase
F cleaves asparagine-linked high mannose as well as hybrid
and complex oligosaccharides from glycoproteins. In our
experiments, both glycosidases resulted in conversion of the
doublet of MMP-28 to the lower molecular weight band
(Figure 3) suggesting that the higher band represents the N-
glycosylated form of MMP-28.Biochemistry Research International 5
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(b) Real-time RT PCR of MMP-28: Total RNA was extracted
from COS-1 cells transfected with GFP control, MMP-28,
and MMP-28 along with furin cDNA. Expression of MMP-
28 mRNA was examined by real-time RT PCR and expression
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(c) Western blotting of the conditioned medium using
anti-Myc antibody: COS-1 cells cotransfected with
MMP-28 cDNA along with wild type and mutant furin
cDNAs. The conditioned medium was examined by
Western blotting using anti-Myc antibodies
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(d) Western blotting of the conditioned medium
and cell lysate using anti-Myc antibody: COS-1 cells
weretransfectedwithfurinalongwithwildtypeand
mutant MMP-28. The conditioned medium and
cell lysate were examined by Western blotting using
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Figure 2: Enhanced secretion of MMP-28 by co-transfection of COS-1 cells with furin cDNA. The data show that MMP-28 secretion
requires coexpression with furin. Furin does not increase newly synthesized MMP-28. Instead, Furin promotes existing MMP-28 secretion
from storage pools to secretory pathway. Active state of furin is not prerequisite.6 Biochemistry Research International
63
49
P
N
G
a
s
e
F
P
N
G
a
s
e
F
b
u
ﬀ
e
r
E
n
d
o
H
b
u
ﬀ
e
r
E
n
d
o
H
Glycosylated
Deglycosylated
Cell lysate
(kDa)
Figure 3: Deglycosylation of MMP-28 examined by Western
blotting. The cell lysate of COS-1 cells transfected with MMP-28
along with furin cDNAs was treated with and without PNGase F
or Endo H. The samples were then examined by Western blotting
using anti-Myc antibodies.
3.2. Requirement of the YL Motif for MMP-28 Secretion. To
further delineate whether the YGYL amino acid sequence
[31] in the propeptide domain of MMP-28 is required
for secretion, a series of point mutations were generated
using a site-directed mutagenesis approach. COS-1 cells
were cotransfected with furin cDNA along with wild-
type and mutant MMP-28/Myc cDNAs. Serum-free con-
ditioned media were collected and MMP-28/Myc secretion
was assessed. The tetrapeptide (YGYL) alanine substitution
mutation resulted in decreased MMP-28 secretion (data not
shown). Among the tetrapeptide of YGYL, the tyrosine-
leucine (Y45L46) amino acid sequence in the propeptide of
MMP-28 is critical for furin-induced secretion of MMP-28.
In contrast to wild-type MMP-28, secreted MMP28Y45L46-AA
wasnotincreasedinthepresenceofcotransfectionwithfurin
cDNA 28 (Figure 2(d)). Mutation of the tyrosine-glycine
(MMP28Y43G44-AA) amino acid sequence has no eﬀect on
MMP-28 secretion (Figure 2(d)). These results suggest that
Tyr45-Leu46 motif is required for MMP-28 secretion.
3.3. Complex Formation between MMP-28 and Furin. Since
furin plays a key nonproteolytic role in MMP-28 secretion,
we pursued the possibility that furin may serve as an
intermolecular chaperone for MMP-28 traﬃcking. To this
end, COS-1 cells were cotransfected with MMP-28/Myc
cDNA along with furin cDNA or GFP cDNA. Cell lysates
were collected and immunoprecipitation of MMP-28/Myc
complexes was performed using mouse monoclonal anti-
Myc antibodies. As shown in Figure 4(a), immunoblotting
employing a rabbit antibody to furin revealed the presence
of a furin-MMP-28 complex. This interaction was also
evident in cells transfected with MMP-28 and constitutively
inactive furin
S-A, suggesting that the interaction between
MMP28-Myc and furin is independent of the activation
status of furin. In the reciprocal coimmunoprecipitation
experiment, MMP28-Myc could also be detected in the
furin-immunoprecipitated complex (Figure 4(b)). As a pos-
itive control for the co-immunoprecipitation experiment,
we conﬁrmed that myc-tagged MT1-MMP forms complexes
with furin (Figure 4(b)).
It has been demonstrated that furin is synthesized in the
endoplasmic reticulum (ER) and then becomes localized to
the TGN and cell surface [40, 41]. Based on our biochemical
data demonstrating complex formation between MMP-28
and furin, we employed a double indirect immunoﬂuores-
cence staining approach followed by confocal microscopy
examination to determine the intracellular localization of
these proteins (Figure 4(c)). By analyzing staining patterns
of MMP-28/Myc and furin in cytoplasmic vesicles from
ﬁve individual cells and 120 stained vesicles in each cell,
an average of 70% MMP-28 was found to colocalize with
furin in the same vesicles in transfected COS-1 cells. Taken
together, these data suggest that furin interacts with MMP-
28 in the secretory vesicles.
3.4. Requirement of a Minimal Motif within the Propeptide
Domain of MMP-28 for Complex Formation with Furin.
Furin has been reported to interact with the propeptide
domain of MMPs containing RXXR motif between the
propeptide domain and the catalytic domain for MMP
activations [7, 23]. To determine if furin also interacts
with other domains for MMP traﬃcking, we piloted the
experiment by employing our previously generated domain
swapping and deletion constructs of MT1-MMP cDNA [33,
42] transfected into COS-1 cells. Coimmunoprecipitation
of cell lysates employing an antibody to MT1-MMP, fol-
lowed by immunoblotting using an antibody to furin, con-
ﬁ r m e dc o m p l e xf o r m a t i o nb e t w e e nM T 1 - M M Pa n df u r i n
(Figure 5(a)). Whereas substitution of the catalytic domain
(MT1-MMP2
Cat) or hemopexin domain (MT1-MMP
Pex)
of MT1-MMP with the corresponding regions of MMP-
2 cDNA did not alter the complex formation, deletion of
the propeptide domain of MT1-MMP (MT
Δpro)r e s u l t e d
in abrogation of complex formation between furin and
MT1-MMP. The failure of interaction between MT1Δpro
with furin was not due to lack of MTΔpro expression,
as evidenced by a Western blotting using anti-MT1-
MMP antibody from an aliquot of the total cell lysate
(Figure 5(a), bottom panel). These data are consistent with
a requirement for the propeptide in complex formation with
furin.
In order to explore which speciﬁc domain of MMP-
28 is required for interaction with furin, we compared the
amino acid sequences of the propeptide domains of MT1-
MMP and MMP-28. This analysis reveals 42% sequence
identity between MT1-MMP and MMP-28 (Figure 1). The
regions with the highest identity are located in the novel
Y43GYL46 motif, near the C-terminal region containing the
PRCGVPDcysteineswitchregioncommontoallMMPs,and
the C-terminal end containing the RKKR furin consensus
sequence. Based on analogy with MT1-MMP, we focused
on the propeptide domain and demonstrated that deletion
of the entire propeptide domain of MMP-28 resulted in
loss of ability of MMP-28 to coimmunoprecipitate with
furin (data not shown). To dissect the role of the YGYL
motif of MMP-28 in its interaction with furin, cDNAs
encoding wild-type and mutant MMP-28 at the YGYL motif
were cotransfected with furin followed by coimmunopreBiochemistry Research International 7
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bodies followed by immunoblotting with anti-Myc monoclonal antibody.
An aliquot of total cell lysate before immunoprecipitation for α/β tubulin
was used as a loading control
Furin Merge
MMP-28/Myc Phase
Myc Ab
Furin Ab
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con-focal microscopy
Figure 4: Complex formation between MMP-28 and furin as examined by coimmunoprecipitation and coimmunostaining.8 Biochemistry Research International
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(b) Coimmunoprecipitation assay using Myc antibody: COS-1 cells
transfected with furin along with wild type and mutant MMP-28 cDNAs.
The cell lysates were immunoprecipitated with anti-Myc monoclonal
antibody followed by immunoblotting with furin polyclonal antibody. An
aliquot of total cell lysate before immunoprecipitation for α/β tubulin was
used as a loading control
Figure 5: Requirement of the propeptide domain of MT1-MMP for complex formation with furin and the YL sequence of MMP-28 for
complex formation and secretion. The YL motif within the propeptide of MMP-28 is necessary.
cipitation. In the subsequent Western blot depicted in
Figure 5(b), the tyrosine-lycine (Y45L46) sequence in the
propeptide of MMP-28 was shown to be critical for complex
formation between MMP-28 and furin. Deletion of YGYL
in the propeptide domain of MMP-28 also resulted in
failure to coimmunoprecipitate with furin (data not shown).
Interestingly, mutation of the furin consensus sequence
( R K K R )w a sf o u n dt oh a v en oe ﬀect on furin complex
formation. In agreement with the coimmunoprecipitation
data, activation of MMP-28 is not a prerequisite for
interaction with furin because substitution of the critical
catalytic glutamic acid residue with alanine (E-A) [29]
of MMP-28 did not interfere with complex formation
between mutant MMP-28 and furin. These data highlight
the critical role of the YL motif in the propeptide domain
of MMP-28 in binding to furin and facilitating MMP-28
secretion.
3.5. Furin Enhances MMP-28-Induced Cell Migration. We
have previously demonstrated that activation of proMMP-
28, as well as proMMP-9 and proMT1-MMP, is not a
prerequisite for enhanced cell migration through uncoated
membranes with 8μmp o r e s[ 34]. To assess the functional
eﬀect of furin on MMP-28-induced cell migration, COS-
1 cells were cotransfected with furin along with MMP-
28 cDNA or GFP cDNA control followed by a transwell
chamber migration assay. In agreement with our previous
observation [34], expression of MMP-28 in COS-1 cells
statistically enhanced cell migration as compared to GFP
control (P = .0058) (Figure 6). MMP-28-induced cell
migration was further enhanced by coexpression with furin
as compared to furin plus GFP cDNA transfected cells (P =
.0005).Furinhadasimilareﬀectonenhancingthemigration
of MT1-MMP cDNA transfected COS-1 cells (Figure 6).
These results support the concept that furin serves as an
intermolecular chaperone to enhanced secretion of MMP-
28 and to facilitate cell migration independent of proteolytic
activity.
4. Discussion
MMP-28, the most recently identiﬁed MMP, has been impli-
cated in important biological and pathological processes
including neuronal development [26], tissue repair [24],
bacterial infection [43], and cancer [29]. In this report, we
present a unique mechanism for MMP-28 secretion in whichBiochemistry Research International 9
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Figure 6: Increased MMP-28 secretion is accompanied with cell
migration. The data show that furin enhances cell migration in
MMP-28 transfected COS-1 cells. This enhancement is accom-
panied by elevated MMP-28 traﬃcking in the secretory pathway.
COS-1 cells transfected with cDNAs as indicated were examined by
transwell migration assay. Each sample was examined as triplicates
andrepeatedthreetimes.Eachbarrepresentsthemean ±SE.(∗P =
.022;∗∗P = .0058; and ∗∗∗P = .0005).
an interaction between the propeptide domain of MMP-28
and furin is a prerequisite for MMP-28 secretion. Contrary
to the classical role of furin in cleaving the propeptide of
MMPs within a furin consensus sequence, furin-induced
cleavage of the propeptide of MMP-28 was not observed.
Alanine substituted mutations within the propeptide of
MMP-28demonstratedthatfurinservesasanintermolecular
chaperone for MMP-28 secretion through direct interaction
with the Tyr45-Leu46 motif in the propeptide domain of
MMP-28.
In our initial studies of the release of MMP-28 from
transfected COS-1 cells, we encountered unexpected dif-
ﬁculties in detection of MMP-28 in conditioned media.
Although MMP-28 was readily detected in the cell lysate,
ectopic expression of MMP-28 in COS-1 cells resulted in
minimal release of MMP-28 into the conditioned medium.
However,coexpressionoffurinwithMMP-28cDNAinCOS-
1 cells resulted in markedly enhanced secretion of proMMP-
28 (Figure 2(a)). The increase of MMP-28 secretion by furin
was not accompanied by upregulation of MMP-28 gene
expression (Figure 2(b)). These data indicates that furin
enhances traﬃcking/secretion of MMP-28.
The YGYL motif is highly conserved in membrane
type MMPs and has been found to be essential for MT1-
MMP plasma membrane localization [31]. Among secretory
MMPs, only MMP-19 and -28 possess this motif in the
propeptide domain. The YGYL motif in MMP-28 is con-
served among the human, mouse, rat, and Xenopus laevis
protein [9]. Using mutagenesis analysis, we demonstrated
that YL of the YGYL motif is critical for coimmunoprecip-
itation with furin and for secretion of MMP-28 secretion
(Figures 2(d) and 5).
Cell secretion of MMP-28 has been reported to be
variable under diﬀerent conditions [44]. MMP-28 has been
reportedtobeactivatedthroughafurincleavagemechanism,
resulting in a change in molecular mass from ∼58kDa to
∼48kDa [39]. This is consistent with the propeptide domain
content of 99 amino acids [9] and a deduced molecular mass
of 11.9kDa. In contrast, we demonstrated that coexpression
of furin with proMMP-28 cDNA in COS-1 cells did not
lead to the activation of MMP-28. Although we identiﬁed a
doublet of MMP-28 in Western blot analysis of transfected
cell lysates and conditioned media, the diﬀerence in mass of
the doublet was ∼5kDa (Figure 2). Employing Endo H and
PNGase F, we demonstrated that the upper band represents a
glycosylated form of MMP-28 (Figure. 3). Murine MMP-28
has also been reported to be N-glycosylated [39].
Secretion of MMP-28 into conditioned media as a furin-
cleaved protein (Mr-48kDa) has been reported with human
HT1080 ﬁbrosarcoma, HeLa cervical cancer cells and A549
lung adenocarcinoma cells transfected with mouse MMP-
28 cDNA [29, 39, 44]. In contrast, Western blot analysis
of conditioned media isolated from transiently transfected
CHO cells identiﬁed latent MMP-28 protein bands of 58,
57, and 52kDa; activated MMP-28 was not observed [39].
The discrepancy between absence of activated MMP-28 in
transfected nonmalignant COS-1 cells (Figure 2) and CHO
cells as compared to activated MMP-28 in transfected cancer
cells cannot be readily explained. Theoretically, preprotein
convertase furin is responsible for activation of MMPs con-
taining furin-consensus sequence [6]. Growing evidence also
indicate that cleavage of MMP, that is MT1-MMP, at furin
consensus sequence is not a prerequisite for the activation of
MT1-MMP [30, 31, 35, 45, 46]. Employing a furin inhibitor,
Dec-CMK, in MT1-MMP expressing VSMCs, Kappert et
al. [47] demonstrated that MT1-MMP enzymatic activity
was not aﬀected by furin inhibitor, suggesting furin is not
required for the MT1-MMP/MMP-2 proteolytic activation
cascade in primary VSMCs. A furin-independent pathway
of MT1-MMP activation has been proposed [48, 49]. These
diﬀerences reﬂect the complication of molecular and cellular
biology and detailed mechanism underlying these diﬀerence
remains to be understood.
In this report, we demonstrated that furin forms a
complex with both MMP-28 and MT1-MMP, involving their
propeptide domains (Figure 5). This interaction appears
to facilitate MT1-MMP plasma membrane traﬃcking and
MMP-28 secretion [30, 31, 35, 36]. Although MMP-28
contains a paired basic amino acid (RKKR) furin cleavage
site between the propeptide and catalytic domains, we
found that mutation at this site in MMP-28 did not
impair furin-enhanced MMP-28 secretion. Furthermore,
constitutively inactive furin possessed unabated ability to
enhance MMP-28 secretion. Confocal microscopy showed
that the co-localization of furin and MMP-28 was detected
intracellularly, primarily in the perinuclear region. Although
this co-localization staining is not in itself conclusive of an
interaction between MMP-28 and furin, our biochemical
data together with the immunocytochemical staining data
demonstrate that MMP-28 indeed interacts with furin in
the secretory pathway. Our data are in agreement with10 Biochemistry Research International
previous reports showing that furin-induced cleavage at
furin consensus sequences of proproteins [IFN-γ[50], zona
pellucida glycoprotein ZP3[50], proneurotrophin-3 [51]] is
not necessary for proprotein traﬃcking/secretion.
MMP-28 has been reported to both enhance [34]a n d
diminish[44]cellmigration.Illmanetal.reportedthatenzy-
matic activity of MMP-28 in human A549 lung carcinoma
is not a prerequisite for enhanced cell migration [29]. In
agreement with these observations, we demonstrated that
transfection of MMP-28 cDNA into COS-1 cells resulted in
enhanced migration; furin co-transfection further facilitated
cellmigration.Incontrast,Maniconeetal.[43]usedaMMP -
28-nullmousepneumoniamodeltodemonstratethatMMP-
28 restrains the migration of macrophages; unidentiﬁed
factors in serum were implicated [52].
In conclusion, we observed a novel role for furin serving
as a chaperone for MMP-28 secretion. This enhanced
secretion is based on interaction of furin with the YL motif
in the propeptide domain of MMP-28. These ﬁndings add to
the list of novel functions of furin and distinct characteristics
of the YGYL domain of selected MMPs.
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